Well done, Xuewu to challenge the medical unfreedom in the U.S.
If you want to know the why and how the Medical Mafia and the pHarmaceutical Cult came together to erect the current Medical Penitentiary and Iatrogenic Kill Machine go here among others:
EPISODE 286 – ROCKEFELLER MEDICINE by Corbett | Nov 2, 2013
THE ASSOCIATION OF AMERICAN PHYSICIANS AND SURGEONS (AAPS) – is a non-partisan professional association of physicians in all types of practices and specialties across the country. Since 1943, AAPS has been dedicated to the highest ethical standards of the Oath of Hippocrates and to preserving the sanctity of the patient-physician relationship and the practice of private medicine.
To ensure that the people of this nation have access to the broad domain of healing and health care information and services, to ensure the right of practitioners of the healing arts to practice, and to educate the public, promote health and well-being, conduct surveys and research, and participate in legislative, regulatory, legal, or public policy-reform and lobbying to accomplish the goal of health freedom.
The hope for a transformation in medical freedom in the United States rests with Robert F. Kennedy Jr.
The method for this change is very simple: have the FDA advocate for medical practices to adhere to Article 37 of the Helsinki Declaration.
Without changing current regulations, it may be challenging for the FDA to directly advocate for Article 37 of the Helsinki Declaration, but it is possible to align with its principles depending on how it is interpreted and implemented.
What is Article 37 of the Helsinki Declaration?
Article 37 primarily states that when no effective treatment exists, doctors, after thorough consideration, may use unproven or experimental treatments to help patients, provided that the patient's informed consent is obtained. This provision aims to protect patients' rights while allowing innovative treatments in emergency or special circumstances.
Background on Current FDA Regulations
In the United States, the FDA's main responsibility is to ensure the safety and efficacy of drugs and medical devices. Under current regulations, unapproved drugs typically need to go through clinical trial procedures and final approval before they can be legally used for patient treatment. While there are stringent restrictions on the use of unproven drugs, the FDA has established certain exceptions, such as:
Expanded Access Programs: Allowing the use of unapproved drugs under specific conditions for patients who meet the criteria.
Compassionate Use: Providing experimental treatments for eligible patients in dire situations.
Possibilities for the FDA to Advocate Article 37
To promote the principles of Article 37 of the Helsinki Declaration, the FDA could take the following actions within the current regulatory framework:
Enhance Expanded Access and Compassionate Use Programs
The FDA could actively promote these existing channels, enabling more patients to access unproven but potentially life-saving treatments.
Encourage Physicians to Follow the Principles
The FDA could incorporate the ideas articulated in Article 37 (e.g., trying experimental therapies in the absence of treatment options) into guidelines for physicians, particularly in extreme or emergency situations.
Strengthen Informed Consent Processes
Even when experimental treatments are used, the FDA could reinforce the importance of obtaining informed consent to ensure compliance with the ethical principles outlined in Article 37.
Support Related Research and Public Dialogue
The FDA could encourage the medical community, academic researchers, and industry groups to discuss Article 37 of the Helsinki Declaration, raise awareness, and optimize existing regulations accordingly.
Challenges and Limitations
Legal Conflicts
Fully adopting Article 37’s principles by relaxing regulatory oversight on experimental drugs may conflict with current laws, especially if robust clinical data on the safety and efficacy of those treatments is not yet available.
Safety and Ethical Concerns
Advocating for Article 37 could raise safety concerns, particularly when using treatments that lack sufficient validation.
Conflict of Interests and Liability
Allowing broader use of experimental treatments could lead to abuse by pharmaceutical companies or expose patients to high medical risks.
Conclusion
Without changing current regulations, the FDA could reflect and advocate for the spirit of Article 37 through measures such as promoting expanded access or compassionate use policies, reinforcing informed consent principles, and supporting discussions on medical ethics. However, systematic and broader implementation of Article 37’s principles may still require adjustments to existing regulations.
Very neat comparison. I wonder how long rhe typically doctor--patient meeting is in other countries. Is it limited to 10-15 minutes like here? I wonder how long the in office wait time is when you make an appointment to see the doctor? Are they often hours behind like here?
A very interesting post. It does occur to me that it could as easily be titled Comparing Medical Bureaucratic Constraints, as opposed to Comparing Medical Freedoms - and that might even be a more accurate title. Freedoms are those things we don't need to pay attention to in our medical environment. They are freely accessible. Constraints define the treatment that patients, and often their doctors as well - are not permitted to access, or are required to pay extra in order to receive. Countries with more and stronger medical constraints negatively affect the natural freedoms of doctors and patients. Calling them "freedoms" is a bit strange.
Well done, Xuewu to challenge the medical unfreedom in the U.S.
If you want to know the why and how the Medical Mafia and the pHarmaceutical Cult came together to erect the current Medical Penitentiary and Iatrogenic Kill Machine go here among others:
EPISODE 286 – ROCKEFELLER MEDICINE by Corbett | Nov 2, 2013
https://corbettreport.com/episode-286-rockefeller-medicine/
THE FLEXNER REPORT: HOW JOHN D. ROCKEFELLER USED THE AMA TO TAKE OVER WESTERN MEDICINE
https://thefreedomarticles.com/amp/flexner-report-rockefeller-ama-takeover/
JOHN ROCKEFELLER: HOW HE TOOK CONTROL OVER MODERN MEDICINE
https://hannenabintuherland.com/usa/john-rockefeller-how-he-took-control-over-modern-medicine/
DEATH BY MEDICINE by Gary Null 2010
https://archive.org/details/DeathByMedicine/page/n15/mode/1up
ON IATROGENIC OR MEDICALLY CAUSED PREMATURE DEATH—
2nd Or 3rd Leading Cause Of Death In Welfare State Countries Worldwide
http://www.huffingtonpost.com/allen-frances/why-are-medical-mistakes-_b_5888408.html
Some push back:
THE ASSOCIATION OF AMERICAN PHYSICIANS AND SURGEONS (AAPS) – is a non-partisan professional association of physicians in all types of practices and specialties across the country. Since 1943, AAPS has been dedicated to the highest ethical standards of the Oath of Hippocrates and to preserving the sanctity of the patient-physician relationship and the practice of private medicine.
https://aapsonline.org/about-aaps/
NATIONAL HEALTH FREEDOM ACTION
The Mission
To ensure that the people of this nation have access to the broad domain of healing and health care information and services, to ensure the right of practitioners of the healing arts to practice, and to educate the public, promote health and well-being, conduct surveys and research, and participate in legislative, regulatory, legal, or public policy-reform and lobbying to accomplish the goal of health freedom.
https://nationalhealthfreedomaction.org/advocacy-info/
Get free, stay free.
The hope for a transformation in medical freedom in the United States rests with Robert F. Kennedy Jr.
The method for this change is very simple: have the FDA advocate for medical practices to adhere to Article 37 of the Helsinki Declaration.
Without changing current regulations, it may be challenging for the FDA to directly advocate for Article 37 of the Helsinki Declaration, but it is possible to align with its principles depending on how it is interpreted and implemented.
What is Article 37 of the Helsinki Declaration?
Article 37 primarily states that when no effective treatment exists, doctors, after thorough consideration, may use unproven or experimental treatments to help patients, provided that the patient's informed consent is obtained. This provision aims to protect patients' rights while allowing innovative treatments in emergency or special circumstances.
Background on Current FDA Regulations
In the United States, the FDA's main responsibility is to ensure the safety and efficacy of drugs and medical devices. Under current regulations, unapproved drugs typically need to go through clinical trial procedures and final approval before they can be legally used for patient treatment. While there are stringent restrictions on the use of unproven drugs, the FDA has established certain exceptions, such as:
Expanded Access Programs: Allowing the use of unapproved drugs under specific conditions for patients who meet the criteria.
Compassionate Use: Providing experimental treatments for eligible patients in dire situations.
Possibilities for the FDA to Advocate Article 37
To promote the principles of Article 37 of the Helsinki Declaration, the FDA could take the following actions within the current regulatory framework:
Enhance Expanded Access and Compassionate Use Programs
The FDA could actively promote these existing channels, enabling more patients to access unproven but potentially life-saving treatments.
Encourage Physicians to Follow the Principles
The FDA could incorporate the ideas articulated in Article 37 (e.g., trying experimental therapies in the absence of treatment options) into guidelines for physicians, particularly in extreme or emergency situations.
Strengthen Informed Consent Processes
Even when experimental treatments are used, the FDA could reinforce the importance of obtaining informed consent to ensure compliance with the ethical principles outlined in Article 37.
Support Related Research and Public Dialogue
The FDA could encourage the medical community, academic researchers, and industry groups to discuss Article 37 of the Helsinki Declaration, raise awareness, and optimize existing regulations accordingly.
Challenges and Limitations
Legal Conflicts
Fully adopting Article 37’s principles by relaxing regulatory oversight on experimental drugs may conflict with current laws, especially if robust clinical data on the safety and efficacy of those treatments is not yet available.
Safety and Ethical Concerns
Advocating for Article 37 could raise safety concerns, particularly when using treatments that lack sufficient validation.
Conflict of Interests and Liability
Allowing broader use of experimental treatments could lead to abuse by pharmaceutical companies or expose patients to high medical risks.
Conclusion
Without changing current regulations, the FDA could reflect and advocate for the spirit of Article 37 through measures such as promoting expanded access or compassionate use policies, reinforcing informed consent principles, and supporting discussions on medical ethics. However, systematic and broader implementation of Article 37’s principles may still require adjustments to existing regulations.
Very neat comparison. I wonder how long rhe typically doctor--patient meeting is in other countries. Is it limited to 10-15 minutes like here? I wonder how long the in office wait time is when you make an appointment to see the doctor? Are they often hours behind like here?
A very interesting post. It does occur to me that it could as easily be titled Comparing Medical Bureaucratic Constraints, as opposed to Comparing Medical Freedoms - and that might even be a more accurate title. Freedoms are those things we don't need to pay attention to in our medical environment. They are freely accessible. Constraints define the treatment that patients, and often their doctors as well - are not permitted to access, or are required to pay extra in order to receive. Countries with more and stronger medical constraints negatively affect the natural freedoms of doctors and patients. Calling them "freedoms" is a bit strange.